Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Christophe Perrin"


2 mentions found


CAPE TOWN, South Africa (AP) — South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. The pills are especially important for South Africa, where TB killed more than 50,000 people in 2021, making it the country’s leading cause of death. In July, J&J’s patent on the drug expired in South Africa, but the company had it extended until 2027, enraging activists who accused it of profiteering. Back then, President Nelson Mandela’s government in South Africa eventually suspended patents to allow wider access to AIDS drugs. Bedaquiline was not rolled out as a standard treatment in South Africa until 2018.
Persons: they’ve, , Brook Baker, Johnson, Christophe Perrin, Peter Maybarduk, Petro Terblanche, Afrigen, Nelson Mandela’s, “ Mandela, Terblanche, Lynette Keneilwe Mabote, Andy Gray, Gray, Zolelwa, Bedaquiline, , Sifumba, ___ Cheng Organizations: Health Organization, Northeastern University, One, Johnson, J, Viiv Healthcare, WHO, Public Citizen, Pfizer, Moderna, Terblanche, Big Pharma, South, University of KwaZulu, World Health Organization, AP Locations: CAPE, South Africa, Colombia, Belarus, Ukraine, Colombian, Washington, Africa, Natal, South African, London
FILE PHOTO-The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. The drug will be available at the lower prices through the Stop TB Partnership's Global Drug Facility, which is the largest procurer of TB treatments. J&J, which sells bedaquiline under the brand name Sirturo, reached an agreement with the Stop TB Partnership in July to allow the coalition to supply generic versions of the drug through the Global Drug Facility. J&J has said it is false to suggest its patents prevent access to the drug. But J&J could further increase access to the drug by withdrawing its secondary patents on bedaquiline in all high-burden countries, said Christophe Perrin, TB advocacy pharmacist with MSF's Access Campaign.
Persons: Johnson, Brendan McDermid, bedaquiline, Atul Gawande, John Green, Médecins, Christophe Perrin, Manas Mishra, Devika Organizations: New York Stock Exchange, REUTERS, Johnson, United Nations, TB, United States Agency, International Development's Global Health Bureau, Drug Facility, Global Drug, Thomson Locations: New York, U.S, Bengaluru
Total: 2